Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out

Lung Cancer. 2014 Jun;84(3):314-5. doi: 10.1016/j.lungcan.2014.03.012. Epub 2014 Mar 15.
No abstract available

Keywords: Adjusted HR; Advanced NSCLC; Docetaxel; Erlotinib; Phase III trial; Second line treatment; Tailor trial.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Clinical Trials, Phase III as Topic
  • Docetaxel
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Quinazolines / therapeutic use*
  • Salvage Therapy / methods
  • Taxoids / therapeutic use*

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Taxoids
  • Docetaxel
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors